Skip to main content
main-content

16.09.2015 | Original Article | Ausgabe 2/2016

Tumor Biology 2/2016

An orally administered DNA vaccine targeting vascular endothelial growth factor receptor-3 inhibits lung carcinoma growth

Zeitschrift:
Tumor Biology > Ausgabe 2/2016
Autoren:
Yan Chen, Xin Liu, Cong Guo Jin, Yong Chun Zhou, Roya Navab, Kristine Raaby Jakobsen, Xiao Qun Chen, Jia Li, Ting Ting Li, Lu Luo, Xi Cai Wang
Wichtige Hinweise
Yan Chen and Xin Liu contributed equally to this work.

Abstract

Lung cancer is the leading cause of mortality and 5-year survival rate is very low worldwide. Recent studies show that vascular endothelial growth factor receptor-3 (VEGFR-3) signaling pathway contributes to lung cancer progression. So we hypothesize that an oral DNA vaccine that targets VEGFR-3 carried by attenuated Salmonella enterica serovar typhimurium strain SL3261 has impacts on lung cancer progression. In this study, the oral VEGFR-3-based vaccine-immunized mice showed appreciable inhibition of tumor growth and tumor lymphatic microvessels in lung cancer mice model. Moreover, the oral VEGFR-3-based vaccine-immunized mice showed remarkable increases in both VEGFR-3-specific antibody levels and cytotoxic activity. Furthermore, the oral VEGFR-3-based vaccine-immunized mice showed a significant increase in the levels of T helper type 1 (Th1) cell intracellular cytokine expression (IL-2, IFN-γ, and TNF-α). After inoculation with murine Lewis lung carcinoma (LLC) cells, CD4+ or CD8+ T cell numbers obviously declined in control groups whereas high levels were maintained in the oral VEGFR-3-based vaccine group. These results demonstrated that the oral VEGFR-3-based vaccine could induce specific humoral and cellular immune responses and then significantly inhibit lung carcinoma growth via suppressing lymphangiogenesis.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Premium-Inhalten der Fachzeitschriften, inklusive eines Print-Abos.

Jetzt abonnieren und bis 25. Juni einen 50 € Amazon-Gutschein sichern.

Weitere Produktempfehlungen anzeigen
Zusatzmaterial
High resolution image (TIFF 7068 kb)
13277_2015_4061_MOESM1_ESM.tif
High resolution image (TIFF 16038 kb)
13277_2015_4061_MOESM2_ESM.tif
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 2/2016

Tumor Biology 2/2016Zur Ausgabe
  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.